Clinical Trial Update: Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of iparomlimab and tuvonralimab (QL1706) with bevacizumab as postoperative adjuvant therapy for hepatocellular carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: The Affiliated Hospital of Xuzhou Medical University | Conditions: HCC - Hepatocellular Carcinoma, Adjuvant Treatment | Phase 2 | Status: NOT_YET_RECRUITING